Gaining an understanding of the specific cellular functions and related pathways of both the wild-type and mutant SETBP1 proteins will be crucial to identify new targets for therapeutic treatment and so improve outcomes for patients with myeloid malignancies who carry SETBP1 mutations. This evidence concerns the gene SETBP1 and myeloid neoplasm.